The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes

NCT01795248 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide can help improve blood sugar control and reduce the risk of type 2 diabetes in women who previously had diabetes during pregnancy.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind prevention study

Participants 105 people

Who can join Ages 18+ · female only Healthy volunteers accepted.

Timeline Started 2012-07 · est. completion 2020-09

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01795248 ↗

Description as written by the study sponsor.

It is well-known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.

Treatments tested

Liraglutide also known as Victoza, NN2211 Drug

1.8 mg liraglutide
Placebo Drug

Liraglutide without the GLP-1 analogue

Main thing measured	Change in glucose tolerance
Sponsor	Tina Vilsboll
Conditions studied	Gestational Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01795248 ↗